Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal

Journal of Nuclear Medicine

Volumn 49, Issue 5, 2008, Pages 764-770

  Tuttle, R Michael ^a   Brokhin, Matvey ^b   Omry, Gal ^a   Martorella, Andrew J ^a   Larson, Steven M ^a   Grewal, Ravinder K ^a   Fleisher, Martin ^a   Robbins, Richard J ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Radioactive iodine; Remnant ablation; rhTSH; Thyrogen; Thyroid cancer

Indexed keywords

IODINE 123; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG UPTAKE; DRUG WITHDRAWAL; FEMALE; HISTOLOGY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; THYROID CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CATHETER ABLATION; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; RISK; THYROGLOBULIN; THYROID NEOPLASMS; THYROTROPIN; TIME FACTORS; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 44149083802     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.049072     Document Type: Article

References (22)

1. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12:49-64.
2. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43:1482-1488.
3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306.
4. Luster M, Felbinger R, Dietlein M, Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid. 2005;15:1147-1155.
5. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-3676.
6. Robbins RJ, Robbins AK. Clinical review 156: recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab. 2003;88:1933-1938.
7. Schlumberger M, Pacini F, Wiersinga WM, et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol. 2004;151:539-548.
8. Sweeney DC, Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am. 1995;24:803-839.
9. Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid. 1997;7:613-619.
10. Schroeder PR, Haugen BR, Pacini F, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006;91:878-884.
11. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
12. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888-896.
13. Robbins RJ, Tuttle RM, Sharaf RN, et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2001;86:619-625.
14. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-932.
15. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88:4110-4115.
16. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063-4068.
17. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433-1441.
18. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002;87:3242-3247.
19. Robbins RJ, Srivastava S, Shaha A, et al. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:6010-6016.
20. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142.
21. 131I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86:4092-4097.
22. Schlumberger M, Pacini F. Thyroid Tumors. 2nd ed. Paris, France: Nucleon; 2003.